Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3740203
Max Phase: Preclinical
Molecular Formula: C23H17BrN2O3
Molecular Weight: 449.30
Molecule Type: Small molecule
Associated Items:
ID: ALA3740203
Max Phase: Preclinical
Molecular Formula: C23H17BrN2O3
Molecular Weight: 449.30
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1ccc(NC(c2ccc(Br)cc2)c2ccc3cccnc3c2O)cc1
Standard InChI: InChI=1S/C23H17BrN2O3/c24-17-8-3-15(4-9-17)20(26-18-10-5-16(6-11-18)23(28)29)19-12-7-14-2-1-13-25-21(14)22(19)27/h1-13,20,26-27H,(H,28,29)
Standard InChI Key: PKCXEKWXPIBUME-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 449.30 | Molecular Weight (Monoisotopic): 448.0423 | AlogP: 5.60 | #Rotatable Bonds: 5 |
Polar Surface Area: 82.45 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.90 | CX Basic pKa: 4.26 | CX LogP: 4.67 | CX LogD: 2.58 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.37 | Np Likeness Score: -0.95 |
1. Mohammed I, Hampton SE, Ashall L, Hildebrandt ER, Kutlik RA, Manandhar SP, Floyd BJ, Smith HE, Dozier JK, Distefano MD, Schmidt WK, Dore TM.. (2016) 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells., 24 (2): [PMID:26706114] [10.1016/j.bmc.2015.11.043] |
Source(1):